Literature DB >> 20186914

Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes.

Matteo Colombo1, Stefania Vallese, Ilaria Peretto, Xavier Jacq, Jean-Christophe Rain, Frédéric Colland, Philippe Guedat.   

Abstract

High-throughput screening highlighted 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile (1) as an active inhibitor of ubiquitin-specific proteases (USPs), a family of hydrolytic enzymes involved in the removal of ubiquitin from protein substrates. The chemical behavior of compound 1 was examined. Moreover, the synthesis and in vitro evaluation of new compounds, analogues of 1, led to the identification of potent and selective inhibitors of the deubiquitinating enzyme USP8.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186914     DOI: 10.1002/cmdc.200900409

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  37 in total

Review 1.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

Review 2.  Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.

Authors:  Anat Ben-Shlomo; Odelia Cooper
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

3.  Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9.

Authors:  Jonathan M Goodwin; William E Dowdle; Rowena DeJesus; Zuncai Wang; Philip Bergman; Marek Kobylarz; Alicia Lindeman; Ramnik J Xavier; Gregory McAllister; Beat Nyfeler; Gregory Hoffman; Leon O Murphy
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

4.  Isopeptidases in anticancer therapy: looking for inhibitors.

Authors:  Andrea Sgorbissa; Harish Potu; Claudio Brancolini
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

5.  USP8 is a novel target for overcoming gefitinib resistance in lung cancer.

Authors:  Sanguine Byun; Sung-Young Lee; Jihoon Lee; Chul-Ho Jeong; Lee Farrand; Semi Lim; Kanamata Reddy; Ji Young Kim; Mee-Hyun Lee; Hyong Joo Lee; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Clin Cancer Res       Date:  2013-06-07       Impact factor: 12.531

6.  Ubiquitin-Specific Proteases as Druggable Targets.

Authors:  Mindy I Davis; Anton Simeonov
Journal:  Drug Target Rev       Date:  2015

Review 7.  From bortezomib to other inhibitors of the proteasome and beyond.

Authors:  Daniela Buac; Min Shen; Sara Schmitt; Fathima Rani Kona; Rahul Deshmukh; Zhen Zhang; Christine Neslund-Dudas; Bharati Mitra; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer.

Authors:  Soyeon Shin; Kyungeun Kim; Hwa-Ryeon Kim; Kris Ylaya; Sung-Im Do; Stephen M Hewitt; Hee-Sae Park; Jae-Seok Roe; Joon-Yong Chung; Jaewhan Song
Journal:  Cell Death Differ       Date:  2019-09-17       Impact factor: 15.828

9.  Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity.

Authors:  Jorg van Loosdregt; Veerle Fleskens; Juan Fu; Arjan B Brenkman; Cornelis P J Bekker; Cornelieke E G M Pals; Jenny Meerding; Celia R Berkers; Joseph Barbi; Andrea Gröne; Alice J A M Sijts; Madelon M Maurice; Eric Kalkhoven; Berent J Prakken; Huib Ovaa; Fan Pan; Dietmar M W Zaiss; Paul J Coffer
Journal:  Immunity       Date:  2013-08-22       Impact factor: 31.745

10.  USP8 is a Novel Therapeutic Target in Melanoma Through Regulating Receptor Tyrosine Kinase Levels.

Authors:  Baoxue Duan; Changying Wang; Zeng Liu; Xiaoyu Yang
Journal:  Cancer Manag Res       Date:  2021-05-24       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.